Completed PHASE1 INTERVENTIONAL NCT00114569

Lorazepam for the Treatment of Status Epilepticus in Children

Use of Lorazepam for the Treatment of Status Epilepticus

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Interventions lorazepam

Updated 8 times since 2017 Last updated: May 20, 2016 Started: Mar 31, 2005 Primary completion: Apr 30, 2007 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00114569, this PHASE1 trial focuses on Status Epilepticus and remains completed. Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jun 2019 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The Emmes Company, LLC

Data source: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Washington D.C., United States